PL-doxorubicin 35-40 mg/m(2) and epirubicin 70mg/m(2) were given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21days for six courses. The choice to adopt the dosage of 30 mg/m2(instead of 50 mg/m2 of conventionaldoxorubicin) was based on pharmacokinetic data and on the results of previous studies in lymphoma.Rituximab 375 mg/m2 was given on day 0 in subsequent courses of therapy. Granulocyte colony-stimulating factor was given in the presence of grade 4 neutropenia or febrile neutropenia until hematological recovery. Treatment was stopped if lymphoma progressed, the patient refused further participation,or if there was any other intercurrent clinical condition or adverse event.
Age
18–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age between 18 and 65 years
Diagnosis of previously-untreated DLBCL(patients with a transformed untreated low-grade lymphoproliferative disease were accepted)
ECOG performance status \< 3 (and higher if due to lym-phoma)
No symptomatic cardiac arrythmias or heart failure
Acceptable renal, hepatic and pulmonary function
Standard laboratory and radiological staging procedures and left ventricular ejection fraction analysis by echocardiography or scintigraphy were required before therapy in all cases
The protocol was approved by the ethics review committee of each partici- pating center
All patients gave informed written consent.
You may not be if
Patients with a previous history of cardiac disease;
HIV-HBsAg-HCV positivity, central nervous system involvement or any other major clinicalcondition;
Other than lymphoma, which might have precluded a regular therapeutic course, were excluded from the study.